Co-crystal forms of selinexor

Inventors

Hamilton, Clifton

Assignees

Karyopharm Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12559478-B2

Patent

Publication Date

2026-02-24

Expiration Date


Abstract

The present invention is directed to selinexor co-crystal forms; more particularly to two co-crystal forms with succinic acid as the coformer and a co-crystal form with vanillin as the coformer. The present disclosure is also related to processes for the preparation of selinexor co-crystal forms. Further, the present invention also relates to pharmaceutical compositions comprising a selinexor co-crystal form and method for treating disease using a selinexor co-crystal form.

Core Innovation

The disclosed invention includes anhydrous selinexor co-crystals with succinic acid in Forms I and II, and with vanillin in Form I. The forms have distinct X-ray powder diffraction fingerprints and are described as co-crystals for pharmaceutical compositions and disease treatment. The disclosure also reports that the succinic acid forms adsorb water, which improves solubility relative to selinexor.

The background section is not included in the provided patent content, so the problem being solved there is not explicitly described in patent. The provided content identifies the co-crystal forms and their characterization, but does not state a specific limitation of prior selinexor forms that the invention addresses. Preparation routes are referenced, but operational details are omitted here.

Claims Coverage

The provided relevant claims include two inventive features directed to selinexor co-crystals with different coformers.

Selinexor and succinic acid co-crystal

A selinexor co-crystal comprising selinexor and succinic acid as a coformer. Dependent claims identify crystalline Forms I and II by their X-ray powder diffraction characteristics.

Selinexor and vanillin co-crystal

A selinexor co-crystal comprising selinexor with vanillin as a coformer. A dependent claim identifies crystalline Form I by its X-ray powder diffraction characteristics.

The independent claims cover two co-crystal compositions: selinexor with succinic acid and selinexor with vanillin. The dependent claims further define crystalline forms and their characteristics.

Stated Advantages

The disclosure states that the succinic acid co-crystal forms adsorb water, which improves solubility relative to selinexor.

Documented Applications

The co-crystal forms are proposed for pharmaceutical compositions and disease treatment, including treatment of relapsed or refractory multiple myeloma.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.